Screener
Alamar Biosciences ALMR Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Alamar Biosciences in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Alamar Biosciences’s 10-Q, filed May 8, 2026.
- Filed
- May 8, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-213424
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Stockholders’ deficit | ||
| Founders preferred stock | — | — |
| Common stock | 1 | 1 |
| Additional paid-in capital | 12,108 | 9,892 |
| Accumulated other comprehensive loss | (80) | (72) |
| Accumulated deficit | (190,100) | (168,775) |
| Total stockholders’ deficit | (178,071) | (158,954) |
| Total liabilities, convertible preferred stock and stockholders' deficit | $186,451 | $139,992 |
Item 1. Financial Statements
FAQ
- What is Alamar Biosciences's total liabilities & equity?
- Alamar Biosciences (ALMR) reported total liabilities & equity of $186.45M in Q1 2026.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Alamar Biosciences's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude